FDA Clears Inovio's Voceryq for Airway Papillomas

FDA granted accelerated approval on 30 October 2026 to Voceryq, Inovio Pharmaceuticals' DNA-plasmid immunotherapy for recurrent respiratory papillomatosis (RRP) — the first product approval in the company's history, arriving on its PDUFA target date after a review in which the agency's own acceptance letter had questioned whether the single-arm evidence package actually qualified for the accelerated pathway.

What Voceryq is, and how it is given

RRP is caused by HPV types 6 and 11 growing as recurrent wart-like papillomas in the airway, typically requiring patients to undergo repeated surgical excisions — sometimes dozens over a lifetime — to keep the airway clear. Voceryq is a therapeutic DNA-plasmid immunotherapy: synthetically designed plasmids encoding HPV-6/11 antigens, delivered intramuscularly with Inovio's proprietary CELLECTRA electroporation device, intended to prime a targeted T-cell immune response against HPV-infected papilloma tissue rather than removing the growths surgically. It is Inovio's lead program and, as of this approval, the company's first product ever cleared by any regulator.

The evidence — and the pathway dispute behind it

The approval rests on Phase 1/2 trial RRP-001, a 32-participant, non-placebo-controlled study, measured against a complete-response endpoint defined as no surgical intervention for the 12 months following treatment. Twenty-six of 32 participants (81%) had at least one fewer surgery than their pre-treatment baseline, and 23 of 32 (72%) had a reduction of half or more. A retrospective follow-up study, RRP-002, tracked 28 of the original participants and reported 86% experiencing a 50-to-100% reduction in surgeries during a second year without additional dosing. Most treatment-related adverse events were low-grade (Grade 1) — injection-site pain and fatigue were the most commonly cited. What makes the approval notable for RA/QA readers is not just the data but the process: FDA's own BLA acceptance letter, issued after Inovio's December 2025 submission, raised as a preliminary review issue that the company had not adequately justified why single-arm Phase 1/2 evidence should qualify for the accelerated-approval pathway rather than requiring a controlled trial. Inovio publicly disagreed, arguing the product addressed a significant unmet need and offered meaningful benefit over existing surgical management, and continued toward the PDUFA date without a reported change in trial design. According to the company's second-quarter 2026 disclosures, a subsequent informal FDA meeting did not revisit the accelerated-approval eligibility question raised in the acceptance letter. The agency approved on schedule.

A second entrant into a market that had one

Voceryq is not the first approved RRP therapy. Precigen's Papzimeos (zopapogene imadenovec-drba), a gene-based immunotherapy delivered by subcutaneous injection, received full FDA approval in August 2025 as the first-and-only approved therapy for adult RRP, backed by a pivotal study that met its pre-specified primary efficacy endpoint without a confirmatory-trial requirement attached. Voceryq's arrival fourteen months later gives RRP patients and their physicians a second option — but one approved on a conditional, single-arm evidentiary basis rather than Papzimeos's unconditional approval, a distinction that matters for how each product's label, post-market obligations and eventual clinical positioning will diverge.

What the confirmatory obligation actually requires

• Timeline is now running. Inovio must submit a draft confirmatory-trial protocol to FDA by the end of 2026 and a final protocol by mid-2027. RA/QA teams tracking the product for formulary, reimbursement or competitive-intelligence purposes should expect the confirmatory trial's design — controlled or not, endpoint selection, enrollment size — to be the next disclosure that actually tests whether this accelerated approval converts to a full one.
• Withdrawal risk is real, not boilerplate. FDA's accelerated-approval statute allows withdrawal if a confirmatory trial fails to verify clinical benefit or is not completed with due diligence. Given that FDA's own acceptance letter had already flagged the evidentiary basis as a preliminary concern, this program sits closer to that risk than a typical accelerated approval built on a single large randomized trial awaiting a confirmatory readout.
• Label and REMS details were not independently reviewed for this report. Regulatory News has not reviewed Voceryq's full prescribing information beyond company and trade-press summaries; sponsors and clinicians relying on dosing, REMS or specific safety-monitoring requirements should consult FDA's approval letter and label directly.

Frequently asked questions

What did FDA approve on 30 October 2026?

Accelerated approval for Voceryq (INO-3107), Inovio's DNA-plasmid immunotherapy, to reduce surgical papilloma excisions in adults with recurrent respiratory papillomatosis — the company's first FDA-approved product.

What evidence supported the approval?

Phase 1/2 trial RRP-001 (n=32): 81% had at least one fewer surgery, 72% had a 50%-or-greater reduction. Follow-up study RRP-002 reported 86% with a 50-to-100% reduction in year two without additional dosing.

Why does the accelerated-approval pathway matter here?

FDA's BLA acceptance letter preliminarily questioned whether the single-arm evidence justified the accelerated pathway; the agency approved anyway. A confirmatory trial is required, with a draft protocol due by year-end 2026 and a final protocol by mid-2027, and FDA can withdraw approval if benefit is not confirmed.

Is this the first approved therapy for RRP?

No. Precigen's Papzimeos received full FDA approval in August 2025 as the first approved RRP therapy. Voceryq is the second, and the first approved on single-arm accelerated-approval evidence.